Sight Diagnostics uses advanced computer-vision and machine-learning technology in the field of blood diagnostics.

The companys initial product, the Parasight platform, is a highly accurate, easy-to-use device for diagnosing malaria.Sight Diagnostics is also applying its technology to the complete blood count (CBC) market, developing a point-of-care CBC platform that will provide a five-point differential blood count for use in doctors offices and emergency medical centers.Beyond its malaria and CBC platforms, the companys computer-vision technology has the potential to unlock advanced diagnostic approaches to numerous additional diseases and provide patients with accurate and inexpensive testing.In December 2019, the company received FDA 510(k) clearance for its OLO analyzer, a device that performs blood tests and provides lab-grade results in minutes.

Tests include the complete blood count (CBC) panel, which comprises the most common and useful tests conducted by medical professionals.